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Reply to the Editor:
I appreciate Murphy and colleagues’ letter
to the editor,1 discussing the differences in
our robotic surgical methods.2,3 To be sure,
both his group and ours have attained ex-
cellent results with robotic mitral valve re-
pairs. He is correct in that we use different
sites for working-port and camera inci-
sions, and this difference definitely facili-
tates hand-tying of intracardiac sutures by
the patient-side surgeon. Nevertheless, we
are traveling toward a totally endoscopic
mitral operation, and the necessity for pa-
tient-side intracardiac assistance to perform
the operation requires 2 experienced sur-
geons. Thus, if we are to become asymp-
totic to “real endoscopic cardiac mitral sur-
gery,” experienced surgeons, such as Dr
Murphy, must strive to achieve repairs us-
ing all robotic techniques, which would
lessen the need for an experienced patient-
side surgeon. Are these points moot or are
they important? When good surgeons dis-
agree, each becomes more circumspect and
these dialogs help us advance our specialty—
“our destiny.” To this end, I appreciate and
respect both Dr Murphy and colleagues’ let-
ter and opinions.
W. Randolph Chitwood, Jr, MD, FACS, FRCS
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Which cell is transferred hepatocyte
growth factor gene?
To the Editor:
I read with interest the article by Shi and
associates,1 titled “Nonviral Gene Transfer
of Hepatocyte Growth Factor Attenuates
Neurologic Injury After Spinal Cord Isch-
emia in Rabbits.” It is already known that
hepatocyte growth factor (HGF) functions
as a powerful angiogenic factor, as well as
a potent neurotrophic factor,2 and HGF is
not expressed in the spinal cord in the early
phase after the ischemia.3 Thus I agree that
gene transfer of HGF could induce toler-
ance against a severe spinal cord ischemic
insult. Furthermore, intrathecal injection of
HGF gene is less invasive than viral injec-
tion to the spinal cord. However, I have one
question. The authors have not demon-
strated that HGF was induced in any cells.
Johnson and associates4 demonstrated that
flunarizine has a protective effect on neu-
rologic recovery after spinal cord ischemia,
and the mechanism of protection involves
inhibition of calcium accumulation rather
than a direct effect on vascular smooth
muscle using spinal cord blood flow mea-
surements. Furthermore, Hayashi and asso-
ciates5 demonstrated that prevention of de-
layed CA1 neuronal death after cerebral
ischemia in the gerbil by subarachnoid
HGF gene transfer is due to the inhibition
of apoptosis through the blockade of Bax
translocation from the cytoplasm to the nu-
cleus. These results suggest that HGF gene
into intrathecal injection may have a protec-
tive effect against neuronal apoptotic cascade
rather than angiogenic effect. Therefore, to
elucidate the mechanism of neuronal protec-
tion, the authors should demonstrate tempo-
ral profiles of HGF in histochemical study or
in in situ hybridization study.
Masahiro Sakurai, MD, PhD
Department of Cardiovascular Surgery
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Reply to the Editor:
My colleagues and I thank Dr Sakurai for
his insightful comments on our recently
published article. Tolerance induced by
gene transfer of hepatocyte growth factor
(HGF) against ischemia insults has been
well described in the literature, including
our study,1,2 in which the question about
which cell was the target for gene transfer
and then expressed with HGF was eclipsed
by the emphasis on the assessment of neu-
roprotective effects and its possible mech-
anisms. We appreciate that the question
raised by Dr Sakurai is very important.
Human HGF was detected in the pia matter
and parenchyma when HGF was trans-
ferred by intracisternal injection using the
same vector. It seemed that multiple cells
might secrete HGF, including neurons.3 Of
cause, only further study is the best answer.
Spinal cord ischemia can induce two kinds
of motor neuron death: necrosis and apo-
ptosis. It is thought that the delayed and
selective motor neuron death, which occurs
a few days after a relatively short period of
spinal cord ischemia (less than 20 minutes
in the rabbit model) accompanied by de-
layed paraplegia, is due to neuronal apo-
ptosis, whereas necrosis usually occurs af-
ter acute ischemia.4 In the current study,
rabbits were subjected to a 30-minute pe-
riod of ischemia, and most animals were
completely paraplegic 1 day after transient
ischemia. The previous work of our depart-
ment showed that a 30-minute period of
ischemia induced almost a total loss of
motor neurons 2 days after reperfusion.5
Therefore, the motor neuron damage in the
current study was mediated mainly through
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necrosis, but not apoptosis. We agree that
HGF might induce neuroprotective effects
through inhibition of apoptotic cascade.
However, it was highly impossible that the
observed neuroprotection of HGF in our
study is due to its antiapoptotic effects.
Enyi Shi, MD, PhD
The First Department of Surgery
Hamamatsu University School of Medicine
Hamamatsu, Japan
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Apical cannulation for aortic
perfusion
To the Editor:
I read with interest the article, “Transapical
aortic cannulation for cardiopulmonary by-
pass in type A atortic dissection opera-
tions,” by Wada and associates1 in the No-
vember 2006 issue of the Journal. I agree
with the authors that this time-tested
method is indeed most suitable and safe in
the management of type A aortic dissec-
tions. However, its applicability may be
further enhanced by two additional maneu-
vers: The first technique is use of a special
double-lumen catheter; the larger-caliber
channel should have an apical port for per-
fusion and the shorter, smaller-caliber
channel should have a port located about
10 cm proximal to the tip and be positioned
in the left ventricle for removal of blood,
which may be seeping into the left side of
the heart. This arrangement eliminates the
need for a separate vent through the right
pulmonary vein as applied by the authors.
The second technique is application of a
“special” aortic crossclamp, the padded
jaws of which hermetically occlude the
aortic lumen but allow passage of the per-
fusion catheter.2 This arrangement pro-
vides added versatility to apical perfusion,
making continuous or intermittent arch per-
fusion possible even with the proximal
aorta open (Figure 1).
The issue of bleeding that the authors
experienced while placing a purse-string
suture into the apex may be effectively
addressed by introducing the perfusion
catheter through a simple stab wound and
placing a 3-pledgeted purse-string suture
after the heart is cold and fully relaxed.
The authors’ addition transesophageal
echo control of the catheter placement adds
additional safety to the method.
Francis Robicsek, MD, PhD
Department of Thoracic
and Cardiovascular Surgery
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Can the consensus statement on
surgery journal authorship be
implemented?
To the Editor:
The “Consensus statement on surgery jour-
nal authorship” is of great interest, not only
for the surgical scientific community, but
for all biomedical research areas. Most im-
portant journals have it in some form and
all agree on the fundamentals. This indi-
cates that the problem, which is addressed,
is widespread. Some questions, however,
have to be added.
How will this statement be implemented?
Can one rely on the honesty of the coau-
thors? Is a simple statement of the authors
for which part they are responsible suffi-
cient?
The attitude in many universities “to
publish or to perish” is a grim reality and
forms a serious obstacle for honesty. It is
an incentive for one to have his or her name
on as many articles as possible, because
career opportunies and promotions depend
on it.
This is especially a problem in a hier-
archy where heads of departments have to
authorize for funds and materials, or super-
vise but without taking part in the research
as such. Young researchers, who want to
build a career, usually depend on their head
Figure 1. Application of the special
“double-padded” clamp and perfusion
cannula. The jaws of the instrument may
be brought into a position to fully occlude
the clamped aorta but still allow the pas-
sage of the unobstructed flow through the
intra-aortic cannula. The double-barreled
cannula allows perfusion through the
larger, longer channel tip, which is placed
into the aorta, and venting through the
shorter, smaller channel, which termi-
nates within the left ventricle. (From Ro-
bicsek F. Apical aortic cannulation: Appli-
cation of an old method with new
paraphernalia. Ann Thorac Surg. 1991;51:
330-32. Reproduced with permission from
The Society of Thoracic Surgeons).
Letters to the Editor
The Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 4 1121
